-- Quarterly Revenues Increase 62% to $11.7 million -- Quarterly Net Income Increases 76.5% to $4.2 million with EPS of $0.11
NEW YORK and HAIKOU, Hainan, China, May 2 /Xinhua-PRNewswire-FirstCall/
-- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI)
which develops, manufactures, and markets generic and branded
bio-pharmaceutical products in China, today announced its financial results
for the first quarter of 2008.
First Quarter 2008 Highlights
-- Revenue increased 62%, to $11.7 million versus Q1 2007.
-- Net income was $4.2 million, up 76.5% versus Q1 2007.
-- Our existing products continue to generate strong sales during the
first quarter of 2008. Sales of Pusen OK have increased by $1 million,
Buflomedil Hydrochloride increased 198%, Gastrodin increased 70%, and
Cefaclor has increased 64% versus Q1 2007.
-- EPS was $0.11, up 57.1% versus Q1 2007.
Revenues for the first quarter of 2008 increased approximately 62% to $11.7 million, from $7.2 million in the first quarter of 2007. The significant increase in revenues was due to expanded production of the China Pharma's product portfolio supported by enhanced marketing efforts. The Company believes that this extraordinary growth should provide investors with confidence in China Pharma's ability to execute on their strategic marketing plan going forward. Therefore, the Company is reiterating that its 2008 full- year revenue growth is expected to exceed 40%.
Gross profit grew 76% to $5.8 million from $3.3 million in the first quarter of 2007. Gross margins were 49.6% compared to 45.6% recorded during the first quarter of 2008 and 2007 respectively. The growth of gross profit and the improved margins were primarily due to the substantial increase in revenues and the decrease in overall production expenses in the first quarter of 2008.
Operating expenses for the three months ended March 31, 2
|SOURCE China Pharma Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved